176 related articles for article (PubMed ID: 37431663)
1. PREPARE: A Stepped-Wedge Cluster-Randomized Trial to Evaluate Whether Risk Stratification Can Reduce Preterm Deliveries Among Patients With Suspected or Confirmed Preterm Preeclampsia.
De Oliveira L; Roberts JM; Jeyabalan A; Blount K; Redman CW; Poston L; Seed PT; Chappell LC; Dias MAB;
Hypertension; 2023 Oct; 80(10):2017-2028. PubMed ID: 37431663
[TBL] [Abstract][Full Text] [Related]
2. PREPARE: protocol for a stepped wedge trial to evaluate whether a risk stratification model can reduce preterm deliveries among women with suspected or confirmed preterm pre-eclampsia.
Dias MAB; De Oliveira L; Jeyabalan A; Payne B; Redman CW; Magee L; Poston L; Chappell L; Seed P; von Dadelszen P; Roberts JM;
BMC Pregnancy Childbirth; 2019 Oct; 19(1):343. PubMed ID: 31590640
[TBL] [Abstract][Full Text] [Related]
3. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial.
Duhig KE; Myers J; Seed PT; Sparkes J; Lowe J; Hunter RM; Shennan AH; Chappell LC;
Lancet; 2019 May; 393(10183):1807-1818. PubMed ID: 30948284
[TBL] [Abstract][Full Text] [Related]
4. Repeat Placental Growth Factor-Based Testing in Women With Suspected Preterm Preeclampsia: A Stratified Analysis of the PARROT-2 Trial.
Hurrell A; Webster L; Sparkes J; Battersby C; Brockbank A; Clark K; Duhig KE; Gill C; Green M; Hunter RM; Seed PT; Vowles Z; Myers J; Shennan AH; Chappell LC;
Hypertension; 2024 Jul; 81(7):1561-1573. PubMed ID: 38708607
[TBL] [Abstract][Full Text] [Related]
5. The feasibility of soluble Fms-Like Tyrosine kinase-1 (sFLT-1) and Placental Growth Factor (PlGF) ratio biomarker in predicting preeclampsia and adverse pregnancy outcomes among medium to high risk mothers in Kuala Lumpur, Malaysia.
Aminuddin NA; Sutan R; Mahdy ZA; Rahman RA; Nasuruddin DN
PLoS One; 2022; 17(3):e0265080. PubMed ID: 35275947
[TBL] [Abstract][Full Text] [Related]
6. Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial.
Mendoza M; Bonacina E; Garcia-Manau P; López M; Caamiña S; Vives À; Lopez-Quesada E; Ricart M; Maroto A; de Mingo L; Pintado E; Ferrer-Costa R; Martin L; Rodríguez-Zurita A; Garcia E; Pallarols M; Vidal-Sagnier L; Teixidor M; Orizales-Lago C; Pérez-Gomez A; Ocaña V; Puerto L; Millán P; Alsius M; Diaz S; Maiz N; Carreras E; Suy A
JAMA; 2023 Feb; 329(7):542-550. PubMed ID: 36809321
[TBL] [Abstract][Full Text] [Related]
7. The predictive value of the sFlt-1/PlGF ratio in suspected preeclampsia in a New Zealand population: A prospective cohort study.
Hughes RCE; Phillips I; Florkowski CM; Gullam J
Aust N Z J Obstet Gynaecol; 2023 Feb; 63(1):34-41. PubMed ID: 35670085
[TBL] [Abstract][Full Text] [Related]
8. Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio and Time to Delivery in Women With Suspected Preeclampsia.
Zeisler H; Llurba E; Chantraine F; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Dinkel C; Schoedl M; Dilba P; Hund M; Verlohren S
Obstet Gynecol; 2016 Aug; 128(2):261-269. PubMed ID: 27399996
[TBL] [Abstract][Full Text] [Related]
9. Associations Between Soluble fms-Like Tyrosine Kinase-1 and Placental Growth Factor and Disease Severity Among Women With Preterm Eclampsia and Preeclampsia.
Hastie R; Bergman L; Walker SP; Kaitu'u-Lino T; Hannan NJ; Brownfoot F; Schell S; Harper A; Cannon P; Cluver CA; Tong S
J Am Heart Assoc; 2022 Aug; 11(16):e024395. PubMed ID: 35943054
[TBL] [Abstract][Full Text] [Related]
10. Role of placental, fetal and maternal cardiovascular markers in predicting adverse outcome in women with suspected or confirmed pre-eclampsia.
Reddy M; Palmer K; Rolnik DL; Wallace EM; Mol BW; Da Silva Costa F
Ultrasound Obstet Gynecol; 2022 May; 59(5):596-605. PubMed ID: 34985800
[TBL] [Abstract][Full Text] [Related]
11. The soluble fms-like tyrosin kinase-1 (sFLT-1) to placental growth factor (PIGF) ratio as a possible indicator for the severity of preeclampsia - single institution experience.
Müller A; Horvat V; Vulin M; Mandić S; Šerić V; Vidosavljević D
Med Glas (Zenica); 2019 Feb; 16(1):53-59. PubMed ID: 30680983
[TBL] [Abstract][Full Text] [Related]
12. Economic assessment of the use of the sFlt-1/PlGF ratio test to predict preeclampsia in Germany.
Schlembach D; Hund M; Schroer A; Wolf C
BMC Health Serv Res; 2018 Aug; 18(1):603. PubMed ID: 30081904
[TBL] [Abstract][Full Text] [Related]
13. Prognostic indicators of severe disease in late preterm pre-eclampsia to guide decision making on timing of delivery: The PEACOCK study.
Duhig KE; Seed PT; Placzek A; Sparkes J; Hendy E; Gill C; Brockbank A; Shennan AH; Thangaratinam S; Chappell LC
Pregnancy Hypertens; 2021 Jun; 24():90-95. PubMed ID: 33770588
[TBL] [Abstract][Full Text] [Related]
14. Omeprazole Administration in Preterm Preeclampsia: a Randomized Controlled Trial to Study Its Effect on sFlt-1 (Soluble Fms-Like Tyrosine Kinase-1), PlGF (Placental Growth Factor), and ET-1 (Endothelin-1).
Neuman RI; Baars MD; Saleh L; Broekhuizen M; Nieboer D; Cornette J; Schoenmakers S; Verhoeven M; Koch BCP; Russcher H; van den Berg SAA; van den Meiracker AH; Visser W; Danser AHJ
Hypertension; 2022 Jun; 79(6):1297-1307. PubMed ID: 35341328
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Preeclampsia Using the Soluble fms-Like Tyrosine Kinase 1 to Placental Growth Factor Ratio: A Prospective Cohort Study of Unselected Nulliparous Women.
Sovio U; Gaccioli F; Cook E; Hund M; Charnock-Jones DS; Smith GC
Hypertension; 2017 Apr; 69(4):731-738. PubMed ID: 28167687
[TBL] [Abstract][Full Text] [Related]
16. Angiogenic factors in maternal circulation and preeclampsia with or without fetal growth restriction.
Vatten LJ; Åsvold BO; Eskild A
Acta Obstet Gynecol Scand; 2012 Dec; 91(12):1388-94. PubMed ID: 22882089
[TBL] [Abstract][Full Text] [Related]
17. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention.
Poon LC; Shennan A; Hyett JA; Kapur A; Hadar E; Divakar H; McAuliffe F; da Silva Costa F; von Dadelszen P; McIntyre HD; Kihara AB; Di Renzo GC; Romero R; D'Alton M; Berghella V; Nicolaides KH; Hod M
Int J Gynaecol Obstet; 2019 May; 145 Suppl 1(Suppl 1):1-33. PubMed ID: 31111484
[TBL] [Abstract][Full Text] [Related]
18. The expression of serum sEGFR, sFlt-1, sEndoglin and PLGF in preeclampsia.
Cui L; Shu C; Liu Z; Tong W; Cui M; Wei C; Tang JJ; Liu X; Hu J; Jiang J; He J; Zhang DY; Ye F; Li Y
Pregnancy Hypertens; 2018 Jul; 13():127-132. PubMed ID: 30177039
[TBL] [Abstract][Full Text] [Related]
19. Placental growth factor in assessment of women with suspected pre-eclampsia to reduce maternal morbidity: a stepped wedge cluster randomised control trial (PARROT Ireland).
Hayes-Ryan D; Khashan AS; Hemming K; Easter C; Devane D; Murphy DJ; Hunter A; Cotter A; McAuliffe FM; Morrison JJ; Breathnach FM; Dempsey E; Kenny LC; O'Donoghue K;
BMJ; 2021 Aug; 374():n1857. PubMed ID: 34389547
[TBL] [Abstract][Full Text] [Related]
20. Angiogenic factors during pregnancy in Asian women with elevated blood pressure in early pregnancy and the risk of preeclampsia: a longitudinal cohort study.
Zhu J; Zhang J; Ng MJ; Chern B; Yeo GS; Tan KH
BMJ Open; 2019 Dec; 9(11):e032237. PubMed ID: 31791965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
